A Correlation of Immunohistochemical and Molecular Detection of Human Papilloma Virus Subtypes 16 and 18

Saleh Hussein Bensumaidea1, Hussain Gadelkarim Ahmed2, Salim Saeed Bafakeer3, Mohammed Siddiq Abd-al-Aziz1, Fawaz D. Alshammari4

1Department of Histopathology and Cytology, Faculty of Medical Laboratory Science, Sudan University for Science and Technology, Sudan
2Department of Pathology, College of Medicine, Molecular Diagnostics and Personalized Therapeutics Unit, University of Hail, KSA; Department of Histopathology and Cytology, FMLS, University of Khartoum, Sudan.
3Department of Pathology, College of Medicine, Hadhramout University of Science and Technology, Yemen.
4Department of Medical Laboratory, College of applied Medical Science, University of Hail.

Abstract: Background: Human papillomavirus (HPV) infection involved in the development of more than 90% of cases of cervical cancer. Therefore, the aim of this study was to assess role of IHC for detection of HPV subtypes 16 and 18, as compared to molecular identification.

Methodology: A total of 84 cervical cancer tissues that were previously diagnosed as having cervical cancer, were investigated for the presence of HPV subtypes 16 and 18. Both immunohistochemistry and molecular (Polymerase Chain Reaction (PCR)).

Results: In application of molecular (PCR) testing for HPV subtypes 16 and 18; 62/84 (73.8%) were found positive for HPV subtype 16 and the remaining 22/84 (26.2%) were negative. On the other hand, on testing the samples for HPV subtype 18; 23/84 (27.4%) were found positive and the remaining 61/84 (72.6%) were found negative.

Conclusion: Immunohistochemistry using clone K1H8 (anti-HPV) is considerably lower-priced, and has reasonable specificity to be applied in Yemen for screening for HR HPV.

Keywords: HPV, cervical cancer, Immunohistochemistry, PCR

1. Introduction

Human papillomavirus (HPV) is a DNA virus from the papillomavirus family that is capable of infecting keratinocytes of the skin or mucous membranes. There are more than 170 HPV-subtypes which are classified into the alpha, beta, gamma, mu, and nu genera [1]. There are more than 40 HPV-subtypes belonging to the alpha genus that cause sexually transmitted infections. These infections are frequently responsible of many pathological conditions such as, condylomas and anogenital intra-epithelial neoplasia. At least 18 of these subtypes are causative agents of anogenital carcinomas [2]. Of the known HPV subtypes, 15 are classified as high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82), 3 as probable high-risk (26, 53, and 66), and 12 as low-risk (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108) [3]. High risk HPV types possess two early (E) oncoproteins (E6 and E7) [4]. The HPV genome is composed of six early (E1, E2, E4, E5, E6, and E7) ORFs, two late (L1 and L2) ORFs, and a non-coding long control region (LCR) [5]. The E6/E7 proteins inactivate two tumor suppressor proteins, p53 (inactivated by E6) and pRb (inactivated by E7) [6].

Cervical cancer was estimated 527,624 new cases in 2012 and 265,653 deaths worldwide [7]. More than 80% of global invasive cervical cancer cases occur in developing countries and almost present with a higher mortality/incidence ratio [8]. Oncogenic types of HPV subtypes are the principal cause of cervical cancer and its precursor lesions [9]. HPV16, 18, 45 and 35 are the most common HPV subtypes in African women with invasive cervical cancer [10].

However, the expression of HPV markers and surrogate markers of HPV infection can be simply estimated by Immunohistochemistry (IHC). Diverse antigens can be used including virus related (capsidic antigens, E5-E6-E7 proteins), and virus induced and/or altered host proteins (p16INK4a, pRb, Cyclin proteins, p-53) [11]. Several authors have stressed that a hallmark of the presence of HPV in cancer could be found in p16 nuclear or cytoplasmic overexpression, so that p16 could be considered a useful surrogate marker for HPV [12,13].

Therefore, the aim of this study was to assess role of IHC for detection of HPV subtypes 16 and 18, as compared to molecular identification.

2. Materials and Methods

A total of 84 cervical cancer tissues that were previously diagnosed as having cervical cancer, were investigated for the presence of HPV subtypes 16 and 18. Both immunohistochemistry and molecular (Polymerase Chain Reaction (PCR)). The diagnosis was based on clinical examination and histological features of the biopsy. The sample included full coverage of patients with cervical cancer.

Immunostained using avidin biotin technique to detect the HPV (L1 capsid protein) by the use of monoclonal mouse...
anti-human papillomavirus clone K1H8 from Dako company which is used to demonstrate HPV type 6, 11, 16, 18, 31, 33, 42, 51, 52, 56 and 58. All sections on silanized coated slides were dewaxed in hot plate oven and cleared in two changes of xylene two minutes for each, hydrated through descending grades of ethyl alcohol (100%, 90%, 70%, 50%) and finally to distilled water, 2 minutes for each change. The sections were boiled in the Target Retrieval Solution of Dako (citrate buffer solution pH 6) in a water bath at 95°C for 30 min, then left to cool at room temperature and washed three times with PBS. 3% hydrogen peroxide in methanol were added to each section for 15 min to block endogenous peroxidase activity, and then washed three times with phosphate buffer saline (PBS) pH 7.4 for 3 minutes, then the diluted monoclonal mouse anti-human papillomavirus clone K1H8 from Dako company was added to each slide for 30 minutes, washed in PBS for 3 min., then treated with biotinylated link for 15 minutes, washed in PBS for 3 min, treated in conjugated streptavidin, washed in PBS for 3 min, then treated with 3,3-diaminobenzidinetetrahydrochlorate (DAB) for 10 minutes, washed in PBS for 3 minutes, then stained in Mayer's haematoxyline as counter stain for one minute, then washed and blued in running tap water, hydrated, cleared and mounted in DPX.

Positive and negative controls from known positive and negative samples were treated as the samples.

3. DNA extraction

DNA was extracted according to the steps described in DNA extraction kit purchased from Sacace biotechnologies-Casera –Italy. The pellet obtained from previous steps was treated with 300 μl of Reagent 2 (lysis buffer) in addition 100 μl of sample, vortexed, incubated at 65°C for 5 min and centrifuged at (12000–16000 g) for 10 min and transfer the supernatant into new tube (sterile 1.5 ml Eppendorf tube) for DNA extraction. Vortexed vigorously sorbent and added 20 μl to each tube, Vortexed for 5–7 sec and incubated all tubes for 3 min at room temperature, then this step was repeated. Then all tubes were centrifugated for 30 sec at 5000 g and used amicropipette with a plugged aerosol barrier tip, carefully removed and discarded supernatant from each tube without disturbing the pellet. Tips was Changed between the tubes. 500 μl of Washing Solution was added to each tube. Vortexed vigorously and centrifuged for 30 sec at 10000 g. Supernatant was removed and discarded from each tube. This step was repeated and incubated all tubes with open cap for 5–10 min at 65°C. The pellet was resuspended in 100 μl of DNA-eluent. Incubate for 5 min at 65°C and vortex periodically. The tubes were centrifuged for 1 min at 12000x g. The supernatant was containing DNA ready for amplification stored at -20°C until used.

3.1 Polymerase chain reaction (PCR) Amplification of HPV

Type specific primers (primer for HPV 16 and HPV18) were used to detect HPV16 and 18. DNA in cervical malignant lesions. Amplification was performed according to HPV16/18 kit from Sacace-Biotechnologies S.r.l. Caserta – Italy. The final reaction volume of 40 μl containing 20 μl mix-1(contained in PCR tubes), 10 μl of mix-2 and 10 μl of extracted DNA (sample). Negative control, positive HPV16 DNA and positive control 18 DNA tubes contained 10 μl of DNA buffer, 10 μl of HPV 16 DNA and 10 μl of HPV18 DNA respectively. Samples and controls were amplified using Gene Amp PCR system 9700.

4. Results

This study investigated 84 tissue samples obtained from patients with cervical cancer their ages ranging from 21-75 with a mean age of 47 years. All of the samples confirmed as positive by immunohistochemical testing using pan anti-human papillomavirus antibody. In application of molecular (PCR) testing for HPV subtypes 16 and 18; 62/84 (73.8%) were found positive for HPV subtype 16 and the remaining 22/84 (26.2%) were negative. On the other hand, on testing the samples for HPV subtype 18; 23/84 (27.4%) were found positive and the remaining 61/84 (72.6%) were found negative.

Regarding age, most of the infected patients were at age range 41-50 years constituting 35/84 (41.7%), followed by age group 31-40, 51+ and 21-30 years, representing, 23/84 (27.4%), 18/84 (21.4%) and 8/84 (9.5%), respectively as indicated in Fig 1. For HPV subtype 16, most of cases were observed at age group 41-50 representing 30/62 (48.4%) followed by age range 31-40 years constituting 15/62 (24.2%). For HPV subtype 18, most of cases were observed at age group 41-50 representing 9/23 (39%) followed by age range 51+ years constituting 7/23 (30.4%), as shown in Fig. 2.

Table 1: Distribution of the study subjects by HR-HPV subtypes 16 & 18 and age

<table>
<thead>
<tr>
<th>Age group</th>
<th>HPV16</th>
<th>HPV18</th>
</tr>
</thead>
<tbody>
<tr>
<td>21-30 years</td>
<td>7</td>
<td>3</td>
</tr>
<tr>
<td>31-40</td>
<td>15</td>
<td>4</td>
</tr>
<tr>
<td>41-50</td>
<td>30</td>
<td>9</td>
</tr>
<tr>
<td>51+</td>
<td>10</td>
<td>7</td>
</tr>
<tr>
<td>Total</td>
<td>62</td>
<td>23</td>
</tr>
</tbody>
</table>

Figure 1: Description of HR-HPV positive cases by age
et al. found multiple subtypes in 6% of adenocarcinoma [22], and Pirog et al. reported 7.6% [23]. These findings suggest that invasive adenocarcinoma growth may be triggered by the actions of a single HPV type, rather than by the synergetic actions of multiple HPVs. However, the molecular negative results in this study may be attributed to multiple infections with subtypes other than 16 and 18 which are known positive with the used antibody in present study.

In the present study, we used anti-human papillomavirus, clone K1H8 (anti-HPV) which reacts with a non-conformational internal linear epitope of a major capsid protein of HPV-1, which is broadly expressed among the different HPV subtypes [26]. Anti-HPV was found to be immunoreactive with FFPE HPV-infected tissues which were demonstrated by Southern blot hybridization to be infected with HPV type6, 11, 16, 18, 31, 33, 42, 51, 52, 56 and 58. Positive immunostaining was largely confined to the nuclei of infected cells. Occasionally, the cytoplasm of koilocytic cells was observed to be immunoreactive[27].

The major limitation of this study is the application of molecular analysis only to HPV subtypes 16 and 18. Future prospect: Further studies are needed to evaluate all HPV subtypes that are expected to be positive K1H8, this in addition to the evaluation of P16 in this context.

In conclusion Immunohistochemistry using clone K1H8 (anti-HPV) is considerably lower-priced, and has reasonable specificity to be applied in Yemen for screening for HR-HPV. The K1H8 antibody reacts with a nonconformational, internal, linear epitope of a major capsid protein of HPV that is specific for HPV subtypes 16 and 18. E6 Protein is suitable choice for detection of these common HR-HPV subtypes.

References


